Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "ITU"

2207 News Found

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission
R&D | October 27, 2025

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission

With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market


Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030
News | October 27, 2025

Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030

Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030


Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance
News | October 25, 2025

Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance

Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions


AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer
Clinical Trials | October 24, 2025

AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer

OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy


Enzalutamide leads to 40% lower risk of death in prostate cancer
Clinical Trials | October 22, 2025

Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting


Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer
Clinical Trials | October 22, 2025

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population


Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
Clinical Trials | October 22, 2025

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab


Roche presents positive phase III data for vamikibart in uveitic macular edema
Clinical Trials | October 22, 2025

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME


Cambrex to invest $120 million to expand API manufacturing in US
News | October 22, 2025

Cambrex to invest $120 million to expand API manufacturing in US

Expanding US operations to address the increased demand for API development and manufacturing